DiaMedica Therapeutics Management
Management criteria checks 2/4
DiaMedica Therapeutics' CEO is Rick Pauls, appointed in Jan 2010, has a tenure of 14.33 years. total yearly compensation is $1.22M, comprised of 46.2% salary and 53.8% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $169.11K. The average tenure of the management team and the board of directors is 2.3 years and 5 years respectively.
Key information
Rick Pauls
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 46.2% |
| CEO tenure | 14.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
May 16
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 12FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
Jul 06We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Jun 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 04DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
Nov 05DiaMedica: Undercovered Stroke Drug Company With Decent Data
Jun 13We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
May 01Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?
Feb 13
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn
Jan 09DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$562k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$18m |
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$15m |
| Dec 31 2022 | US$1m | US$523k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$13m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$1m | US$477k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$878k | US$455k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$2m | US$420k | -US$11m |
| Sep 30 2019 | n/a | n/a | -US$10m |
| Jun 30 2019 | n/a | n/a | -US$9m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$734k | US$315k | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$5m |
| Jun 30 2018 | n/a | n/a | -US$4m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$502k | US$280k | -US$4m |
Compensation vs Market: Rick's total compensation ($USD1.22M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
CEO
Rick Pauls (52 yo)
14.3yrs
Tenure
US$1,215,161
Compensation
Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 14.3yrs | US$1.22m | 0.18% $ 169.1k | |
| CFO & Corporate Secretary | 6.1yrs | US$632.22k | 0.085% $ 81.7k | |
| Independent Consultant | 2.3yrs | US$596.08k | 0% $ 0 | |
| Chief Technology Officer | less than a year | no data | no data | |
| Chief Commercial Officer | 2.3yrs | no data | 0.0074% $ 7.1k | |
| Chief Business Officer | 1.1yrs | no data | 1.39% $ 1.3m | |
| Chief Medical Officer | less than a year | no data | no data |
2.3yrs
Average Tenure
55yo
Average Age
Experienced Management: DMAC's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 19.1yrs | US$1.22m | 0.18% $ 169.1k | |
| Independent Director | 8.6yrs | US$90.76k | 0.0059% $ 5.7k | |
| Independent Director | 13.8yrs | US$90.93k | 0.85% $ 816.9k | |
| Member of Kidney Scientific Advisory Board | 5yrs | no data | no data | |
| Independent Chairman | 15yrs | US$133.98k | 0.37% $ 357.9k | |
| Member of Kidney Scientific Advisory Board | 5yrs | no data | no data | |
| Member of Kidney Scientific Advisory Board | 5yrs | no data | no data | |
| Member of Stroke Advisory Board | 1.3yrs | no data | no data | |
| Member of Stroke Clinical Advisory Board | no data | no data | no data | |
| Member of Kidney Scientific Advisory Board | no data | no data | no data | |
| Member of Stroke Clinical Advisory Board | no data | no data | no data | |
| Member of Kidney Scientific Advisory Board | 5yrs | no data | no data |
5.0yrs
Average Tenure
62yo
Average Age
Experienced Board: DMAC's board of directors are considered experienced (5 years average tenure).